Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0250 plus bortezomib + dexamethasone in refractory and relapsed multiple myeloma
2016-002771-10Phase 2Completed
- Sponsor
- Molecular Partners AG
- Start
- Nov 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MP-0250 in multiple myeloma (MM), sponsored by Molecular Partners AG. Primary endpoint: Primary safety endpoint (Part 1). Started Nov 2016; status: completed.
02
Drugs
MP-0250
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-002771-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002771-10.